NKD Advisory LLC’s Post

Congratulations to Northwestern University #startup Cour Pharmaceuticals Development Co., Inc.! COUR announced a strategic collaboration and licensing agreement with Genentech, a member of the Roche Group, for the development and commercialization of COUR’s proprietary #tolerogenic #nanoparticle treatments for an #autoimmune disease. COUR, launched from the work of Northwestern University - The Feinberg School of Medicine Professor Stephen Miller and Professor Lonnie Shea, is a clinical-stage #biotechnology company developing first-in-class, disease-modifying therapies designed to induce #antigen-specific tolerance for #immune-mediated diseases. COUR is currently enrolling patients in a phase 1b/2a double-blind, placebo-controlled, multicenter clinical study in #MyastheniaGravis and developing a product candidate in Type 1 #Diabetes in addition to having completed first-in-human studies in #Celiac Disease (partnered with Takeda) and #PrimaryBiliaryCholangitis. Innovation and New Ventures Office Dannielle Appelhans Brian Bock https://lnkd.in/gx_3ssRC

# Only put off until tomorrow what you are willing to die having left undone ## Don't Miss Out on the Future of Healthcare Investment! 💪💰📈 Athira Pharma Presents Promising Preclinical Data on ATH-1105 for Neuroprotection in ALS at International Symposium \*\*Summary:\*\* Athira Pharma, Inc., a clinical-stage biopharmaceutical company, stole the limelight at the Motor Neurone Disease Association’s International Symposium on ALS/MND in Montreal. The company presented preclinical data showcasing the neuroprotective effects of their drug, ATH-1105, in the treatment of ALS \(Amyotrophic Lateral Sclerosis\). The promising results presented by Athira Pharma have created an exciting opportunity for investors looking to make a difference in the healthcare industry while growing their Health Savings Account \(HSA\). ALS is a devastating disease that affects thousands of individuals worldwide, making advancements in treatment a matter of utmost importance. Investing in healthcare not only aligns with the goal of preserving and improving our own health, but it also supports cutting-edge research and development that can transform lives. By leveraging the potential of your HSA, you have the chance to contribute to breakthrough treatments like ATH-1105 and be at the forefront of medical progress. Take action now to secure a promising future by investing in innovative healthcare companies like Athira Pharma. Don't miss out on the incredible opportunities in the healthcare sector that can shape the well-being of our families and communities. #hsa #investing #healthcare #health #family #wellness 🏥💼👨⚕️💪🌱👪

🎉 Exciting news! Eight leading organizations in the clinical trials industry have united as founding members of the Biospecimen Management Consortium, hosted by Slope. The BMC will spearhead initiatives to set best practices, establish industry standards, streamline biospecimen lifecycle operations, enhance data management, and shape regulatory policy. Stay tuned for updates on their journey @BiospecimenManagementConsortium and dive into their goals at the link below. #BiospecimenConsortium #BiospecimenManagement #ClinicalTrials

We’re celebrating a great achievement today! Eight organizations across the clinical trials industry have joined together as founding members of the Biospecimen Management Consortium. Hosted by Slope, the BMC will drive a variety of initiatives aimed at developing best practices and industry standards; streamlining biospecimen lifecycle operations and data management; and influencing regulatory policy. You can follow along with their journey @Biospecimen Management Consortium and read more about their goals at the link below.#BiospecimenConsortium #BiospecimenManagement #ClinicalTrials

Today, at USBio'24 in San Diego, 🇺🇸? If so, join the #orphan and #rare disease presentations track (Theater 4) and watch live Avanzanite Bioscience corporate presentation. Eva Cruz de Castro will emphasise what is the role of #orphan specialty pharmaceutical company and our strong beliefs to ensure that NO ONE IS LEFT BEHIND when facing monstrous #rare diseases. She will also share our view on the evolving #orphandrug market with anticipated 800+ R&D programs in the global biotechs. And options available for partners how to make their innovations available in Europe and globally. You should particularly watch Eva Cruz de Castro if you face challenges in Europe 🇪🇺 and beyond. Perhaps, there are very few patients that could use your medicine. Or the market access issues are overwhelming. Or simply, you only have a bandwith to go to to 2–3 countries at launch. At Avanzanite Bioscience, whatever is the trouble, we love challenges.

30 Million European Patients Need Your Rare Disease Therapy: Navigate Market Access Now Europe's rare disease market is booming, but many life-saving therapies face barriers to entry. Our latest article, "The Geopolitics of Hope," reveals how to unlock this market's vast potential. Gain expert insights on: 💚 Navigating the complexities of European regulatory and commercial landscapes 💚 Overcoming reimbursement challenges and securing market access 💚 Building effective partnerships with stakeholders 💚 Partnering to accelerate your success Don't miss this essential guide for biotech and pharma companies developing rare disease therapies. https://lnkd.in/e2PZnDJ9 #raredisease #orphandiseases #genetherapy #pharma #biotech #marketaccess #EU #ema #drugdevelopment #patientcentricity

📈 𝗧𝗵𝗲 𝗥𝗶𝘀𝗲 𝗼𝗳 𝗕𝗶𝗼𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗦𝗶𝘁𝗲𝘀 𝗶𝗻 𝗙𝗿𝗮𝗻𝗰𝗲 As the biotherapeutics market rapidly evolves, the demand for bioproduction sites in France is surging. With 𝟱𝟭 𝗯𝗶𝗼𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝘀𝗶𝘁𝗲𝘀, France stands out as one of the leaders in the industry in Europe. These sites play a crucial role in advancing the development and production of biotherapeutics, ensuring that groundbreaking treatments can reach patients. The strategic investment in bioproduction capabilities not only strengthens the healthcare ecosystem but also fosters economic growth and job creation. 👉 𝗝𝘂𝗹𝘆 𝟱𝘁𝗵, 𝟮𝟬𝟮𝟰, France hosts the inaugural 𝗡𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗗𝗮𝘆 𝗼𝗳 𝗕𝗶𝗼𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗕𝗶𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, organised by the diverse members of France BioLead. This event is dedicated to exploring the future of the pharmaceutical industry. In Toulouse, the event is proudly supported by Bio'Occ : projet Biothérapie et Bioproduction en Occitanie, Eurobiomed, and Leem. #Bioproduction #Biotherapeutics #JNBB2024

Top-Down Drug Discovery™ prioritizes a molecule’s function, versus its chemical structure, to identify pharmacologically privileged drugs to engage therapeutic targets in novel ways. LifeMine has the ability to significantly improve the speed of drug discovery comparable to the standard practice of “bottom-up” discovery which includes many complex, time-consuming steps, and is often labor and resource intensive, therefore unscalable to meet the demands of the future.   We’re in uncharted territory, discovering and developing novel precision medicines against high-impact disease targets – including those previously deemed undruggable – with unprecedented speed, predictability, and scalability.    Discover more from our Co-Founder and CEO, Greg Verdine, below.

GPCRs, a network of ~400 genes, represent a critical class of drug targets, accounting for 40% of FDA-approved drugs. Traditional drug discovery focuses on one GPCR at a time, limiting the scope of potential therapies. Chromovert® Technology changes that by enabling multiplexed drug discovery—accessing all 400 GPCRs simultaneously—opening up unprecedented opportunities for drug development. Chromovert® has been validated to access GPCRs with significantly improved results, even for some of the most scientifically challenging targets. By scaling up to target the entire GPCR network, Chromovert® can yield drug candidates with maximal activity and minimal side effects—creating a robust pipeline of novel therapies for a wide range of diseases. A new era of drug discovery is here—one that targets the entire GPCR network in parallel. Read the seminal publication by Secondcell Bio CEO, Dr. Kambiz Shekdar, PhD https://lnkd.in/d7j7ZKM #DrugDiscovery #GPCR #Biotechnology #Chromovert #DrugDevelopment #PrecisionMedicine #FDA #Research #Innovation

We're thrilled to announce the official launch of the Biospecimen Management Consortium, an alliance of industry leaders committed to driving sample excellence in clinical research. Founding members — including GRAIL, GSK, ILiAD Biotechnologies, LLC, Moderna, Novartis, Roche, Takeda, and Teal Health — will address longstanding inefficiencies and gaps in biospecimen lifecycle management that must be addressed to improve data quality and patient outcomes. Together, the consortium will: - Develop best practices and industry standards - Streamline biospecimen lifecycle operations and data management - Shape the future of regulatory policy We look forward to working with these organizations to transform biosample operations, and we commend them for their unwavering dedication to creating a brighter future in clinical research. To read the full press release, click here: https://lnkd.in/gKxTBBRp #BiospecimenConsortium #BiospecimenManagement #ClinicalTrials